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Background: The hypothesis that regular treatment aimed at achieving and maintaining
asthma control is accompanied by reduced airway hyper-responsiveness (AHR) was investi-
gated.
Methods: Adult patients (PC20 methacholine <8 mg/ml, FEV1% predicted 70%) received sal-
meterol/fluticasone propionate combination 50/250 mg bd (SFC250) for a 12-week run-in;
those achieving well-controlled (WC) asthma were randomised to SFC250 (n Z 88) or SFC50/
500 mg bd (SFC500) (nZ 90) for 24 weeks. AHR (PC20 methacholine), asthma control, lung func-
tion, symptoms, exacerbations and safety were assessed.
Results: During the 12 week run-in (SFC250), a greater than 1 doubling dose increase in PC20
was observed. During randomised treatment, the increase in AHR was similar, and less than
1 doubling dose, for both groups (adjusted geometric mean PC20 (mg/mL) at 24 weeks:
SFC250: 2.796, SFC500: 2.802; p Z 0.992). Compared with SFC250, patients receiving
SFC500 had a more rapid improvement in AHR (adjusted mean ratio to baseline respectively
at week 4: 1.193 vs. 1.386; week 12: 1.395 vs. 1.672; pZ non-significant for both) and showed
a greater response to treatment in patients with a low baseline PC20. Patients maintaining WC
asthma were 72 (84%) and 64 (74%) in the SFC250 and SFC500 groups respectively. Both doses of
SFC were well tolerated; only four exacerbations were reported, all in the SFC500 group.
Conclusion: Regular treatment with SFC resulted in continuous improvement in AHR with
maintenance of asthma control in the majority of patients. SFC500 showed a trend for a moreivmed.fr (P. Chanez).
0 Elsevier Ltd. All rights reserved.
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Asthma is a chronic inflammatory disorder causing
increased airway hyper-responsiveness (AHR) and episodic
symptoms of wheezing, breathlessness, chest tightness and
coughing.1 Airway inflammation and AHR are frequently
present when patients are asymptomatic2e4 and there is no
established relationship between asthma control, severity
and level of inflammation; even patients with mild asthma
show evidence of inflammation and airway remodelling.5,6
The aim of asthma management is to achieve and
maintain asthma control by treating inflammation and
relieving bronchoconstriction and symptoms.1 Treatment
guidelines recommend inhaled corticosteroids (ICS) as the
most effective controller medication with the addition of
a long-acting b2-agonist (LABA) in the form of a combination
therapy being advocated as the preferred add-on therapy
when symptoms are not adequately controlled on ICS
alone.1,7 Despite these recommendations, most patients
remain sub-optimally controlled.8,9
Salmeterol/fluticasone propionate combination (SFC) has
been shown to significantly reduce inflammatory markers
and AHR compared with fluticasone propionate alone,10,11
which may be related to the emerging evidence that LABAs
potentiate the anti-inflammatory effects of ICS.10,12 In
asthma, epithelial dysfunction may impair beta adreno-
ceptor function and thus contribute to AHR; and as LABAs
have a beneficial impact on epithelial cell proliferation, this
activity may help to protect against AHR.13 In addition, the
stepwise increase in dose in the Gaining Optimal Asthma
ControL (GOAL) study showed that the majority of patients
treated with SFC could achieve and maintain a composite,
guideline-derivedmeasure of asthma control.14 The speed of
response of individual control criteria was shown to
vary, suggesting that assessment of one criterion may over-
estimate control, emphasising the importance of basing
treatment changes on composite control.15
The current study postulated, in line with Woolcock’s
model,16 that regular treatment with SFC 50/250 mg bd (SFC
250), aimed at achieving and maintaining control of
asthma, would be associated with a reduction in AHR. A
higher dose of SFC, 50/500 mg bd (SFC500), was included as
a comparator to determine if there was any additional
benefit from an increased dose.
Methods
Patients
Maleor female patients, 18 years of age and older,with ahistory
of asthma of at least six months, a PC20 methacholine (PC20)
gethacholine causing forced
all by 20% from post-saline<8 mg/ml and forced expiratory volume in 1 s (FEV1) % pre-
dicted 70% were recruited from 33 centres in 10 European
countries. All patients were seen on an outpatients basis.
PatientswererequiredtohavereceivedFP100mgbdto250mgbd
or equivalent with or without a LABA for at least 4 weeks before
the run-in period. Patients who had either been hospitalized for
their asthma, had a respiratory tract infection, had received
systemic corticosteroidswithin the last 4weeks, orwere current
smokerswereexcluded.At theendof the12week run-inperiod,
patientswhohad their asthmaassessed aswell-controlled (WC),
based on assessment over the last 8 weeks, were eligible for
randomisation. A week of GINA1-derived WC asthma as defined
previously, was no night-time awakenings, no exacerbations, no
emergency visits, no treatment-related adverse events enforc-
ing a change in therapy, and having 2 out of 3 of: symptom score
>1h on 2 days, rescue b2-agonist use on 2 days and 4
occasions per week, and daily morning peak expiratory flow
(PEF)80% predicted.14
Study design
This multi-centre, stratified, double-blind, randomised,
parallel-group study was conducted in 34 centres in 10
European countries. Following a 12 week open-label, run-in
period, during which all patients received SFC250, those
assessed as having WC asthma, were randomised to either
continue treatment with SFC250 or to receive SFC500, for
24 weeks. Randomisation was stratified according to
previous ICS dose (ICS dose FP 100 mg bd or equivalent or FP
250 mg bd or equivalent) and AHR at randomisation visit
(PC20  2 mg/ml or < 2 mg/ml). Both treatments were
supplied by GlaxoSmithKline (GSK) in identical Diskus
devices to blind treatment. Patients were assessed at
Weeks 4, 12 and 24 of treatment. The study was approved
by a national, regional, or investigational centre ethics
committee or institutional review board according to local
laws and regulations. Written informed consent was
obtained from each patient prior to any study-specific
procedures.
Efficacy assessments
The primary endpoint was mean change in PC20 following 24
weeks of treatment. Methacholine challenges were per-
formed by the standardised 2 min tidal breathing method,17
using Provocholine (Methapharm Inc, Brantford, Canada).
Response was expressed as the provocative concentration
causing a 20% fall in post-saline FEV1 (PC20), calculated by
linear interpolation of two adjacent data points. Patients
who completed the challenge to the highest dose of 32 mg/
ml without achieving a 20% fall, were included in the
analysis as having a PC20 of 64 mg/ml. Methacholine chal-
lenge was not performed if baseline FEV1 was <70%h Symptom score: 1 was defined as ‘symptoms for one short
period during the day’; overall scale: 0 (none) to 5 (severe).
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a short course of oral corticosteroids. An increase in PC20 of
1 doubling dose is considered a clinically relevant
improvement.
Secondary endpoints were asthma control, lung function
PEF, FEV1 and forced vital capacity [FVC]), asthma symp-
toms, rescue medication use and exacerbations.
The proportion of patients maintaining WC asthma (see
definition above) or achieving Totally Controlled (TC)
asthma was assessed over the last 8 weeks of treatment. A
week of TC asthma was defined as no symptoms, no rescue
medication use, no night-time awakenings, no exacerba-
tions, no emergency visits, no treatment-related adverse
events enforcing a change in therapy and daily morning PEF
80% predicted.14
Spirometry was performed according to European
Community for Coal and Steel (ECCS) recommendations;18
patients were asked to refrain from using short-acting
bronchodilators for at least 6 h and study medication for
36 h prior to each visit. The highest of three PEF
measurements were recorded each morning prior to taking
any study or rescue medication. A score for asthma symp-
toms over the last 24 h was recorded each morning (scale
from 0 representing ‘no symptoms’ to 5 representing
‘symptoms so severe that patient could not go to work or
perform normal activities’).
Asthma exacerbations were monitored throughout the
study and defined as a deterioration of asthma requiring
administration of oral corticosteroids and/or deterioration
in asthma requiring emergency room visit and/or admission
to hospital.
Safety assessments
Safety was assessed by the monitoring of adverse events.
Such data were collected throughout the study including
serious adverse events and any events which, in the
opinion of the clinician, were considered related to
treatment.
Statistical analyses
Based on the number of patients required to detect
a single doubling dose difference in PC20, with 90%
power, a sample size of 60 evaluable patients per group
was estimated. All analyses were based on the Intention-
to-Treat population and significance testing used a two-
sided test conducted at the 0.05 significance level. Mean
change from baseline in PC20 at Week 24 was compared
using an analysis of covariance (ANCOVA) model, allowing
for effects due to treatment, baseline (randomisation)
PC20, pre-study ICS dose, age, sex and country amal-
gamation. The proportion of patients with WC and TC
asthma were compared using separate logistic regression
models, and the change from baseline in pre-bronchodi-
lator FEV1 and FVC were analysed using ANCOVA. All
efficacy data for PEF, asthma symptoms and rescue
medication use, and all safety data were summarised.
Tests for two-factor interactions between treatment and
pre-study ICS dose, age, baseline PC20, country amal-
gamation and sex were performed (pre-defined signifi-
cance level of 0.10).Results
Patient characteristics
A total of 369 patients were screened for entry to the
study of which 178 were randomised to double-blind
treatment, 88 to SFC 250 and 90 to SFC500 (Fig. 1). The
two groups were well matched both demographically and
for baseline lung function and symptom scores. Values
were consistent with the randomisation of patients with
WC asthma (Table 1). Baseline (end of run-in) values for
PEF and FEV1 were slightly higher in the SFC500 group, as
was baseline mean PC20 (SFC500: 1.77 mg/mL; SFC 250:
1.48 mg/mL) (Table 1)
Efficacy assessments
Run-in
During the 12 week run-in period (treatment SFC250), there
was a greater than 1 doubling dose increase in PC20 in both
groups: SFC250 increase from 0.64 mg/mL to 1.48 mg/mL;
SFC500 increase from 0.67 mg/mL to 1.77 mg/mL (Table 1,
Fig. 2). Mean PEF and FEV1 also increased during the run-in
period (Table 1).
Randomised treatment period
PC20 methacholine
During the 24 week randomised treatment period PC20
increased in both treatment groups with a less than 1
doubling dose increase observed in both groups (end of run-
in baseline to week 24 geometric mean: 1.62e2.80 mg/mL
in the SFC250 group and 1.83e2.80 mg/mL in the SFC500
group, pZ 0.992) (Table 2, Fig. 2). However over the entire
SFC treatment period (including run-in), a greater than
two-fold improvement in AHR was observed in both groups.
At the randomisation visit (end of run-in) 11 (13%) patients
in the SFC250 group and 15 (17%) patients in the SFC500
group demonstrated AHR within the normal range (>8 mg/
mL). At subsequent visits, the number of patients with
a PC20>8 mg/mL for SFC250 and SFC500 respectively: Week
4: 15 (17%) and 19 (21%); Week 12: 18 (20%) and 23 (26%);
Week 24: 23 (26%) and 20 (22%).
For both groups, a faster improvement in PC20 was
observed in the first 12 weeks of randomised treatment
followed by a smaller improvement from week 12 onwards
(Fig. 2). Compared with SFC250, a more rapid improvement
was observed with SFC500, evidenced by a greater PC20
adjusted geometric mean ratio to baseline at weeks 4 and
12 of treatment, although these differences were not
statistically significant (Table 2).
A significant interaction with treatment and baseline
PC20 was observed (p Z 0.047), the model estimating that
patients who started with a lower baseline PC20 had
a better treatment response to the higher dose of SFC than
those who started with a higher baseline PC20 (Fig. 3).
Secondary efficacy assessments
The results for secondary efficacy assessments are sum-
marised in Table 3. Over the last eight weeks of randomised
treatment, the majority of patients in both groups main-
tained their WC asthma status with no significant difference
Patients screened 
369 
Patients randomised 
178 
SFC250
88 
SFC500 
90 
Completed 
85 
Completed 
86 
Withdrawn 3
Consent w/d 1
Adverse event 1
Other 1
Withdrawn 191 
Did not meet e/c 157
Consent w/d 17
Adverse event 8
Lost to follow-up 2
Other 7
Withdrawn 4
Consent w/d 2
Exacerbation 1
Other 1
Figure 1 Subject flow through the study. SFC250 Z salmeterol/fluticasone propionate combination 50/250 mg bd,
SFC500 Z salmeterol/fluticasone propionate combination 50/500 mg bd, w/d Z withdrawn, e/c Z entry criteria.
1104 P. Chanez et al.between groups in the odds of maintaining WC asthma vs
losing WC status (Odds Ratio SFC500 to SFC250: 0.58; 95%
CL: 0.23, 1.43; p Z 0.235). Approximately a quarter of
patients in each group achieved Totally Controlled asthma
(meaning no clinical symptoms) over the last 8 weeks of
treatment.
Patients assessed as not WC over the last 8 weeks of
treatment showed less improvement in PC20 over 24 weeks
than those assessed as having WC or TC asthma. HoweverTable 1 Demography and baseline characteristics.
Parameter SF
Mean Age (range) (years) 44
Male Sex, n (%) 34
PC20
a (mg/mL),
Geometric mean (CV)
Start of run-in 0.6
End of run-in 1.4
Lung function, mean (SD)
Start of run-in: PEF (L/min) 45
FEV1 (L) 2.9
% predicted FEV1 93
End of run-in: PEF (L/min) 47
FEV1 (L) 3.0
% predicted FEV1 94
Mean Symptoms(SD) during run-in
24 h symptom score 0.3
Night-time awakenings 0.0
a Provocative concentration of methacholine causing forced expirat
SFC250Z salmeterol/fluticasone propionate combination 50/250 mg b
500 mg bd; SD Z standard deviation; CV Z coefficient of Variation.improvement in the WC patients was greater than those
assessed as TC: PC20 geometric mean ratio [CV] of Week 24
to baseline values [mg/mL] for the whole study population
(i.e. not split by treatment group): No WC asthma: 1.26
[209.82]; WC asthma: 1.75 [243.35]; TC asthma: 1.53
[276.89] (Fig. 4).
There was a small difference between treatment groups
in change in FEV1 over treatment in favour of the SFC500
group (treatment difference 80 mL, p Z 0.048) (Table 3).C250 (N Z 88) SFC500 (N Z 90)
.4 (18e71) 42.1 (18e73)
(39) 48 (53)
4 (303.70) 0.67 (336.83)
8 (575.10) 1.77 (574.33)
9.0 (95.7) 472.0 (96.8)
6 (0.88) 3.10 (0.78)
.4 (14.9) 89.7 (15.1)
3.5 (100.07) 485.2 (93.69)
0 (0.88) 3.17 (0.78)
.9 (15.4) 91.8 (14.0)
4 (0.36) 0.36 (0.39)
3 (0.19) 0.04 (0.23)
ory volume in 1 s (FEV1) to fall by 20% from post-saline baseline;
d, SFC500Z salmeterol/fluticasone propionate combination 50/
SFC 250 (N=88) SFC 500 (N=90)
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Figure 2 PC20 methacholine over time. —-— SFC50/250 run-
in, then SFC50/250 randomised treatment—:—SFC50/
250 run-in, then SFC50/500 randomised treatment.
SFC 50/250 Z salmeterol/fluticasone propionate combination
50/250 mg bd, SFC50/500Z salmeterol/fluticasone propionate
combination 50/500 mg bd. Y-axis is on the log scale. Difference
between treatments non-significant.
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symptoms were observed and were similar in both treat-
ment groups.
During treatment very few exacerbations were reported.
No patients in the SFC250 group had an exacerbation and
four patients in SFC500 group each had one exacerbation.
Of these, none resulted in hospitalization and three
required treatment with oral corticosteroids.Table 2 PC20 Methacholine.
PC20 Methacholine
a (mg/mL) SFC
Screening, geometric mean (CV) 0.6
Baseline,b geometric mean (CV) 1.6
Week 4, n
Meanc ratio to baseline (CV)
84
1.1
SFC500/SFC 250 ratio (SE)
95% CI
p-Valuec
Week 12, n
Meanc ratio to baseline (CV)
82
SFC500/SFC 250 ratio (SE)
95% CI
p-valued
Week 24, n
Meanc ratio to baseline (CV)
81
SFC500/SFC 250 ratio (SE)
95% CI
p-valued
SFC250Z salmeterol/fluticasone propionate combination 50/250 mg b
500 mg bd; CV Z coefficient of variation; SE Z standard error.
a Provocative concentration of methacholine causing forced expirat
b Includes only patients who also had a week 24 PC20 measurement
c Adjusted geometric mean.
d statistical comparison used ANCOVA model of Log2 (PC20 Ratio to B
ICS dose, age, sex and country amalgamation.Safety assessments
Overall, both doses of SFC were well tolerated with a similar
proportion of patients reporting an adverse event in each
group: 39 (44%) patients in the SFC250 group and 36 (40%)
patients in the SFC500 group. Nasopharyngitis was the most
commonly reported event in both groups (16% and 13%
respectively). The incidence of serious adverse events and
drug-related events was very low for both treatment groups.
Discussion
This study showed that, in adult patients with well-
controlled asthma, treatment with SFC250 or SFC500 for 24
weeks resulted in a continuous improvement in AHR
together with maintenance of asthma control in the
majority of patients. These results are important as they
support the view that a strategy based on regular and
continued treatment with SFC, during which control is
achieved and maintained, can contribute to a potential
change in asthma severity, making a valid contribution to
the concept that sustained treatment may result in sus-
tained improvement of disease characteristics.
These results reinforce the importance of the time-
course for changes in AHR and show that this is the case
even for patients who appear to have clinically controlled
asthma. Although during randomised treatment the
increase in PC20 was less than 1 doubling dose, when the
run-in is considered, a greater than two-fold improvement
in PC20 was demonstrated over 9 months. In a study eval-
uating the effect of high dose FP (750 mg bd), Ward et al4
also showed that the time-course for improvement in
spirometry, inflammation, airway remodelling and AHR was250 (N Z 88) SFC500 (N Z 90)
4 (303.70) 0.67 (336.84)
2 (483.53) 1.83 (619.14)
9 (12.93)
83
1.39 (13.01)
1.16 (0.22)
0.855, 1.578
0.335
; 1.40 (14.68) 86 1.67 (14.31)
1.20 (0.25)
0.852, 1.687
0.295
; 1.62 (15.55) 82 1.63 (15.45)
1.00 (0.27)
0.696, 1.442
0.992
d, SFC500Z salmeterol/fluticasone propionate combination 50/
ory volume in 1 s (FEV1) to fall by 20% from post-saline baseline.
, accounting for difference from baseline shown in Table 1.
aseline), adjusted for baseline, Log2(PC20), pre-study medication
Figure 3 PC20 methacholine at week 24 by baseline PC20.--- Z salmeterol/fluticasone propionate combination 50/250 mg
bd; Z salmeterol/fluticasone propionate combination 50/500 mg bd. Y-axis is on the log scale.
1106 P. Chanez et al.discordant, concluding that prolonged treatment is
required for maximal benefit in airway remodelling and
AHR. The importance of monitoring AHR in the long-term
management of asthma was demonstrated withTable 3 Secondary efficacy assessments.
Asthma Control, weeks 17e24, n
Maintained WC asthma, n (%)
Achieved TC asthma, n (%)
Unevaluable
Pre-bronchodilator FEV1 (L)
Mean change (SE)a
Treatment difference (95% CI)
p-Valueb
Pre-bronchodilator FVC (L)
Mean change (SE)a
Treatment difference (95% CI)
p-valueb
Mean Morning PEF (L/min) (SD)
Baselinec
Weeks 17e24
Mean 24-h Asthma symptom score (SD)
Baselinec
Weeks 17e24
Mean Night-time awakenings (SD)
Baselinec
Weeks 17e24
Mean Median Rescue Medication Use (SD)
Baselinec
Weeks 17e24
a Week 24, adjusted mean change from baseline.
b Statistical comparison used ANCOVA model of change from baselin
sex and country amalgamation.
c Baseline over weeks 8 to 1; WC Z well-controlled; TC Z
SFC250Z salmeterol/fluticasone propionate combination 50/250 mg b
500 mg bd; FVC Z forced vital capacity; PEF Z peak expiratory flowa treatment strategy aimed at decreasing AHR in addition
to the recommendations in existing guidelines, resulting in
better outcomes for exacerbation rates (a strong criterion
for asthma control), lung function and markers ofSFC250 (N Z 88) SFC500 (N Z 90)
86 86
72 (84) 64 (74)
24 (28) 22 (26)
4 (5) 6 (7)
0.04(0.03) 0.04 (0.03)
0.08 (0.00, 0.16)
0.048
0.05(0.036) 0.02(0.036)
0.03 (0.07, 0.13)
0.526
469.9 (95.9) 484.8 (95.0)
478.5 (97.1) 491.8 (93.6)
0.34 (0.36) 0.36 (0.39)
0.23 (0.35) 0.30 (0.52)
0.03 (0.19) 0.04 (0.23)
0.04 (0.20) 0.03 (0.20)
0.05 (0.26) 0.07 (0.41)
0.08 (0.28) 0.08 (0.49)
e, adjusted for baseline PC20 pre-study medication ICS dose, age,
totally controlled; FEV1 Z forced expiratory volume in 1 s;
d, SFC500Z salmeterol/fluticasone propionate combination 50/
; SD Z standard deviation.
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Figure 4 PC20 methacholine ratio to baseline values by
control status: Not Well-Controlled, N Z 26; At Least Well-
Controlled includes Well-Controlled and Totally Controlled
patients, NZ 135; Totally Controlled, NZ 45. Y-axis is on the
log scale.
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alone.19 However, Koenig et al. showed that, for most
patients, improvement in AHR was maintained when
a treatment strategy aimed at controlling clinical parame-
ters alone was used.20 The CATO study group found, in
a group of moderate asthmatic children, that a treatment
strategy guided by AHR showed no benefits in terms of
symptom-free days but produced a better long-term
outcome on FEV1, particularly in a sub-group exhibiting low
symptom scores but with associated AHR.21 Therefore,
current treatment guidelines, based on symptoms and lung
function alone, could result in anti-inflammatory treatment
being stepped down too early in patients with persisting
AHR in the absence of symptoms. A recent American
Thoracic Society/European Respiratory Society Task Force
identified the need to consider the relationship between
control, severity and phenotypes in the context of treating
asthma and assessing future risk. The authors suggested
that characterizing populations by their phenotype can
provide important additional information to the assessment
of current clinical control,22 and the findings of our study
are consistent with this view.
The results of our study concur with the findings of a one
year study by Lundback et al. showing that regular treat-
ment with SFC resulted in significantly fewer exacerbations
and greater improvements in AHR compared with treat-
ment with monotherapy with either FP or salmeterol.11 A
subsequent, two year open extension showed that clinical
control could be maintained over three years following
physician-driven treatment changes: 73% patients were
treated with SFC to maintain control compared with FP
alone (21%) or salmeterol alone (5%). AHR continued to
improve over the three years.23 The results are also
consistent with the GOAL study, demonstrating that regular
treatment with SFC results in achieving and maintaining
clinical control.14 In our study, the benefits on asthma
control appear to be related more to the regular use oftreatment rather than the dose used. The statistically
significant difference in FEV1 in favour of the high dose
group was not considered clinically significant. No signifi-
cant benefit of the increased dose was observed in this
study for PC20 which concurs with the findings of Reddel
et al. who demonstrated, in patients with poorly controlled
asthma, that a daily dose of 1600 mg budesonide resulted in
optimal control in most patients with no additional benefit
derived from a starting dose of 3200 mg24 However, in our
study an interesting interaction between treatment and
baseline PC20 was investigated and indicated that patients
with a lower baseline PC20 showed a better response to the
higher dose of SFC. In addition, the improvements in the
SFC500 group appeared to be achieved more rapidly, as
evidenced by a higher, albeit non-significant, PC20 at weeks
4 and 12 of treatment. A more rapid improvement in AHR
was also observed by the Reddel group during the first 8
weeks of treatment with budesonide 3200 mg daily
compared with 1600 mg daily.24 Therefore a sub-group of
patients with a low PC20 may benefit the most from a higher
starting dose of SFC.
AHR is a marker of the natural history or severity of the
disease rather than a criteria for control (long term vs.
short term).22 The importance of measuring bronchial
responsiveness was also demonstrated by the SAPALDIA
group who showed that, in formerly asymptomatic
patients, AHR was a risk factor for accelerated decline in
FEV1 and development of asthma.
25 Similarly, Limb et al.
demonstrated that factors in childhood that could identify
individuals at risk for irreversible lung function deficits in
adulthood included abnormal spirometry, low PC20 and
duration of asthma.26
The number of exacerbations reported was higher in the
SFC500 group compared with SFC 250 (four vs. none
respectively), although a treatment duration of 24 weeks
may be considered too short to gather meaningful data on
exacerbations. However, this rate is very low and consis-
tent with the low rates of exacerbations reported in other
studies with SFC.14,27 The overall incidence of serious
adverse events, drug-related events and withdrawals due
to events was very low, and no safety issues or significant
differences between treatments were identified.
In conclusion, this study showed that regular treatment
with SFC resulted in continuous improvement in AHR with
maintenance of asthma control in the majority of patients.
SFC500 showed a trend for a more rapid improvement in
AHR and resulted in greater improvements in patients with
a lower baseline PC20. Notably, changes in AHR as a marker
of disease modification takes longer than clinical control,
and studies are needed to identify the appropriate time to
initiate step-down therapy.Acknowledgements
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